Rigel Retained Earnings from 2010 to 2024

RIGL Stock  USD 1.02  0.07  7.37%   
Rigel Pharmaceuticals Retained Earnings yearly trend continues to be quite stable with very little volatility. Retained Earnings may rise above about -1.3 B this year. Retained Earnings is the cumulative amount of net income that Rigel Pharmaceuticals retains for reinvestment in its operations, rather than distributing it to shareholders as dividends. View All Fundamentals
 
Retained Earnings  
First Reported
2000-12-31
Previous Quarter
-1.4 B
Current Value
-1.4 B
Quarterly Volatility
451.8 M
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Rigel Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Rigel Pharmaceuticals' main balance sheet or income statement drivers, such as Depreciation And Amortization of 1.7 M, Interest Expense of 7.2 M or Total Revenue of 122.7 M, as well as many indicators such as Price To Sales Ratio of 2.05, Dividend Yield of 0.0 or Days Sales Outstanding of 63.95. Rigel financial statements analysis is a perfect complement when working with Rigel Pharmaceuticals Valuation or Volatility modules.
  
Check out the analysis of Rigel Pharmaceuticals Correlation against competitors.
For more information on how to buy Rigel Stock please use our How to buy in Rigel Stock guide.

Latest Rigel Pharmaceuticals' Retained Earnings Growth Pattern

Below is the plot of the Retained Earnings of Rigel Pharmaceuticals over the last few years. It is the cumulative amount of net income that a company retains for reinvestment in its operations, rather than distributing it to shareholders as dividends. Rigel Pharmaceuticals' Retained Earnings historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Rigel Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
ViewLast Reported (1.41 B)10 Years Trend
Slightly volatile
   Retained Earnings   
       Timeline  

Rigel Retained Earnings Regression Statistics

Arithmetic Mean(1,044,912,833)
Coefficient Of Variation(35.07)
Mean Deviation271,746,933
Median(1,138,854,000)
Standard Deviation366,401,622
Sample Variance134250.1T
Range1.4B
R-Value(0.89)
Mean Square Error29559.9T
R-Squared0.80
Slope(73,075,880)
Total Sum of Squares1879502.1T

Rigel Retained Earnings History

2024-1.3 B
2023-1.4 B
2022-1.4 B
2021-1.3 B
2020-1.3 B
2019-1.3 B
2018-1.2 B

Other Fundumenentals of Rigel Pharmaceuticals

Rigel Pharmaceuticals Retained Earnings component correlations

0.81-0.24-0.01-0.13-0.09-0.140.990.34-0.01-0.17-0.210.910.140.46-0.210.350.160.2-0.09-0.170.09
0.81-0.620.4-0.41-0.6-0.690.850.0-0.32-0.54-0.70.940.160.81-0.610.620.680.63-0.56-0.610.44
-0.24-0.62-0.260.260.710.75-0.320.230.130.530.68-0.370.08-0.520.38-0.23-0.81-0.780.620.64-0.49
-0.010.4-0.26-0.48-0.6-0.690.04-0.32-0.89-0.45-0.570.310.50.83-0.880.790.650.59-0.46-0.550.33
-0.13-0.410.26-0.480.720.55-0.17-0.230.50.330.51-0.34-0.35-0.560.49-0.46-0.6-0.50.30.68-0.03
-0.09-0.60.71-0.60.720.9-0.150.210.470.560.93-0.41-0.26-0.720.68-0.52-0.92-0.840.790.92-0.6
-0.14-0.690.75-0.690.550.9-0.210.410.570.70.91-0.46-0.09-0.810.78-0.62-0.95-0.810.790.83-0.59
0.990.85-0.320.04-0.17-0.15-0.210.29-0.07-0.24-0.260.930.130.5-0.270.390.250.29-0.12-0.230.1
0.340.00.23-0.32-0.230.210.410.290.310.240.350.130.25-0.130.35-0.25-0.34-0.30.330.17-0.34
-0.01-0.320.13-0.890.50.470.57-0.070.310.350.41-0.28-0.32-0.670.88-0.78-0.6-0.520.160.50.0
-0.17-0.540.53-0.450.330.560.7-0.240.240.350.63-0.42-0.33-0.560.55-0.43-0.65-0.710.540.5-0.5
-0.21-0.70.68-0.570.510.930.91-0.260.350.410.63-0.54-0.25-0.750.73-0.56-0.87-0.810.880.89-0.78
0.910.94-0.370.31-0.34-0.41-0.460.930.13-0.28-0.42-0.540.290.71-0.530.60.460.49-0.39-0.440.33
0.140.160.080.5-0.35-0.26-0.090.130.25-0.32-0.33-0.250.290.44-0.360.340.10.34-0.21-0.240.3
0.460.81-0.520.83-0.56-0.72-0.810.5-0.13-0.67-0.56-0.750.710.44-0.830.790.770.69-0.63-0.70.48
-0.21-0.610.38-0.880.490.680.78-0.270.350.880.550.73-0.53-0.36-0.83-0.84-0.77-0.710.490.73-0.39
0.350.62-0.230.79-0.46-0.52-0.620.39-0.25-0.78-0.43-0.560.60.340.79-0.840.60.55-0.43-0.480.3
0.160.68-0.810.65-0.6-0.92-0.950.25-0.34-0.6-0.65-0.870.460.10.77-0.770.60.91-0.67-0.880.46
0.20.63-0.780.59-0.5-0.84-0.810.29-0.3-0.52-0.71-0.810.490.340.69-0.710.550.91-0.61-0.790.49
-0.09-0.560.62-0.460.30.790.79-0.120.330.160.540.88-0.39-0.21-0.630.49-0.43-0.67-0.610.62-0.92
-0.17-0.610.64-0.550.680.920.83-0.230.170.50.50.89-0.44-0.24-0.70.73-0.48-0.88-0.790.62-0.49
0.090.44-0.490.33-0.03-0.6-0.590.1-0.340.0-0.5-0.780.330.30.48-0.390.30.460.49-0.92-0.49
Click cells to compare fundamentals

About Rigel Pharmaceuticals Financial Statements

There are typically three primary documents that fall into the category of financial statements. These documents include Rigel Pharmaceuticals income statement, its balance sheet, and the statement of cash flows. Rigel Pharmaceuticals investors use historical funamental indicators, such as Rigel Pharmaceuticals's Retained Earnings, to determine how well the company is positioned to perform in the future. Although Rigel Pharmaceuticals investors may use each financial statement separately, they are all related. The changes in Rigel Pharmaceuticals's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Rigel Pharmaceuticals's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Rigel Pharmaceuticals Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Rigel Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Retained Earnings-1.4 B-1.3 B
Retained Earnings Total Equity-1.2 B-1.3 B

Becoming a Better Investor with Macroaxis

Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as Rigel Pharmaceuticals using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.

Build Optimal Portfolios

Align your risk with return expectations

By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations

Additional Information and Resources on Investing in Rigel Stock

When determining whether Rigel Pharmaceuticals is a strong investment it is important to analyze Rigel Pharmaceuticals' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Rigel Pharmaceuticals' future performance. For an informed investment choice regarding Rigel Stock, refer to the following important reports:
Check out the analysis of Rigel Pharmaceuticals Correlation against competitors.
For more information on how to buy Rigel Stock please use our How to buy in Rigel Stock guide.
You can also try the Financial Widgets module to easily integrated Macroaxis content with over 30 different plug-and-play financial widgets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Rigel Pharmaceuticals. If investors know Rigel will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Rigel Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
(0.48)
Earnings Share
(0.11)
Revenue Per Share
0.684
Quarterly Revenue Growth
0.133
Return On Assets
(0.08)
The market value of Rigel Pharmaceuticals is measured differently than its book value, which is the value of Rigel that is recorded on the company's balance sheet. Investors also form their own opinion of Rigel Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Rigel Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Rigel Pharmaceuticals' market value can be influenced by many factors that don't directly affect Rigel Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Rigel Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Rigel Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Rigel Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.